# MaRS Innovation

MaRS Innovation is an Asset Manager based in Toronto, Canada.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Toronto, Canada
- **Region:** North America
- **Address:** Toronto, Ontario, Canada
- **Founded:** 2008
- **Assets under management:** $500 million – $1 billion (Altss estimate)
- **Website:** marsinnovation.com
- **LinkedIn:** https://www.linkedin.com/company/toronto-innovation-acceleration-partners

## Regulatory record

- **Reports private funds:** No

## About

MaRS Innovation was founded in 2008 as a not-for-profit seed fund, one of several created through the Canadian federal government's Networks of Centres of Excellence program. It operates as a consortium representing 20+ member institutions across Ontario and Quebec — including the University of Toronto, McMaster University, and the Hospital for Sick Children — pulling invention disclosures from those institutions into a single pipeline. The fund typically invests at the seed to Series A stage, writing checks of roughly CAD$500K to $2M per deal. Its portfolio spans AI/ML, digital health, clean energy, and advanced manufacturing. Notable alumni include Deep Genomics (AI drug discovery) and BenchSci (AI for antibody selection, per The Globe and Mail, 2021). The firm co-invests with Canadian VCs such as BDC Capital, Real Ventures, and angel networks — it does not lead rounds past Series A. MaRS Innovation is headquartered in Toronto with offices in Montreal and Vancouver. In July 2024, the firm announced the close of its latest fund, MaRS Innovation Fund II, at CAD$45M (per the firm, July 2024), backed by federal and provincial development funds and institutional LP commitments from pension funds and endowments. The structural differentiator is its consortium model — instead of a traditional VC LP base, MaRS Innovation draws its capital from government development funds, university endowments, and a small group of institutional LPs. Its mandate is to commercialize Canadian university IP, which forces it to prioritize technology readiness over market timing. The succession plan centers on CEO Raphael Hofstein, who has held the role since inception.

## Sectors

- AI/ML
- Digital Health
- Enterprise Software
- ClimateTech
- Energy Transition & Renewables
- Robotics & Automation
- Industrial Tech

## Offices

- Montreal
- Vancouver

## Questions

### Who runs investment decisions at MaRS Innovation?

CEO Raphael Hofstein has led the firm since its founding in 2008. The investment committee includes representatives from member universities and external experts. Deal flow is generated from disclosures by the 20+ consortium institutions (public record).

### What investment stages does MaRS Innovation typically target?

Seed and Series A rounds of CAD$500K to $2M. The firm occasionally participates in later rounds for existing portfolio companies. Its focus is on technology readiness and corporate formation (per the firm's official communications).

### Which sectors does MaRS Innovation explicitly avoid?

The firm does not invest in pure biotech (drug discovery) or consumer internet. Its portfolio concentrates on hard-science, deep-tech areas where university IP offers a technical edge (public record).

## Related profiles

- [ULLICO](https://altss.com/profile/ullico)
- [Essex Bio-Technology Limited](https://altss.com/profile/essex-bio-technology-limited)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/mars-innovation

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology